Journal
CUREUS JOURNAL OF MEDICAL SCIENCE
Volume 14, Issue 8, Pages -Publisher
SPRINGERNATURE
DOI: 10.7759/cureus.28479
Keywords
upper extremity; neoadjuvant; sonic hedgehog; basal cell carcinoma; vismodegib
Categories
Ask authors/readers for more resources
This article describes three cases of locally advanced basal cell carcinoma (BCC) of the extremities treated with vismodegib, resulting in significant clinical responses and tumor size reduction, eliminating the need for complex reconstructive surgery or amputation.
Basal cell carcinoma (BCC) is a common skin malignancy that can present reconstructive challenges in patients with locally advanced diseases of the extremities. This article highlights three cases of locally advanced BCC of the extremities managed with vismodegib (Erivedge, Genentech). Vismodegib is a sonic hedgehog pathway (Shh) inhibitor approved by the FDA for use in metastatic or recurrent BCC. All three patients in our case series demonstrated significant clinical responses with reductions in tumor size which obviated the need for complex reconstructive surgery or amputation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available